Loading
A phase 1/2 trial of Elranatamab, Pomalidomide, Dexamethasone in multiple myeloma, run by AstraZeneca, now recruiting.
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma is a phase 1/2 interventional study registered as NCT06106945 by AstraZeneca, with 226 participants planned, started 2023-12-05 and due to reach its primary completion in 2027-08-16. Interventions recorded: AZD0305, Elranatamab, Pomalidomide, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pomalidomide, Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Dexamethasone, Multiple myeloma.
Shares Elranatamab, Pomalidomide, Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Dexamethasone, AstraZeneca, Multiple myeloma.
Shares Elranatamab, Pomalidomide, Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Dexamethasone, Multiple myeloma.
Shares Elranatamab, Dexamethasone, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/